Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Generate Biomedicines, Inc.NASDAQ: GENB

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization of $3.27M in Q1 FY2026

Q1 FY2026 depreciation & amortization was $3.27M.

Context

  • Depreciation & amortization amounted to 41.3% of revenue in FY2025, down 33.7 pp from a year earlier.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.27M— QoQ
Last fiscal yearDec 2025
$13.18M-14.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-14.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
13.18M USD
Year-over-year change
-14.1%
1-year CAGR
-14.1%

Depreciation & Amortization vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 depreciation & amortization of $13.18M is the 2nd highest of the 5 companies compared; the peer median is $9.05M.
  • Its year-over-year change of -14.1% is the lowest of 5, against a peer median of -9.4%.
  • Depreciation & amortization amounts to 41.3% of revenue for GENB, versus a peer median of 113.9%.
GENB Competitors Peer median
Depreciation & Amortization for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$32.16M -7.6%-4.5%47.4%
GENBGenerate Biomedicines, Inc.FY2025$13.18M -14.1%—41.3%
ABSIAbsci CorporationLTM Mar 2026$11.4M -12.6%-3.4%620.8%
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M -8.9%-4.0%6.7%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$2.35M -9.8%+26.6%180.4%
Peer median (excluding GENB) $9.05M-9.4%-3.7%113.9%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.46M31.89M
Cost of Revenue00
Gross Profit20.46M31.89M
Gross Margin100.0%100.0%
Research & Development175.31M224.7M
Selling, General & Admin42.09M42.26M
Operating Expenses217.4M266.96M
Depreciation & Amortization15.35M13.18M
EBITDA(163.71M)(208.49M)
EBITDA Margin-800.2%-653.7%
Operating Income(196.94M)(235.07M)
Operating Margin-962.6%-737.0%
Interest Income18.12M13.66M
Interest Expense2.12M1.14M
Other Income / Expenses15.77M12.26M
Income Before Tax(181.17M)(222.8M)
Pre-Tax Margin-885.5%-698.6%
Income Tax Expense212K163K
Net Income(173.77M)(203.15M)
Net Margin-849.4%-637.0%
EPS (Basic)(1.68)(4.98)
EPS (Diluted)(1.68)(4.98)
Weighted Avg Shares127.45M50.09M
Weighted Avg Shares (Diluted)127.45M50.09M

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.